Mithridion, a drug development company, co-founded by Jeff Johnson, professor in the Pharmaceutical Sciences Division, began a Phase 1 clinical trial of MCD-386, a small-molecule compound designed to treat Alzheimer’s patients.

As highlighted in the July 11, 2008 edition of the Wisconsin State Journal, the goal of the initial testing will be to determine the safety of the compound and the way it is metabolized by humans.